Skip to main content
. 2020 Nov 24;10:592757. doi: 10.3389/fonc.2020.592757

Figure 1.

Figure 1

High expression of SNHG7 was correlated with an adverse response to NCT and poor RFS. (A, B) The relative SNHG7 expressions in BC patients with different molecular subtypes and different response to NCT, including complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD). (C) The relative SNHG7 expression levels were associated with response to NCT. (D) The expression of SNHG7 in the pCR group compared with that in the Non-pCR group. (E) The Kaplan–Meier survival curve of patients with advanced breast cancer classified as low- and high-SNHG7 groups based on a median expression level of SNHG7. *P < 0.05.